<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t3-ir-2019-09155" orientation="portrait" position="float">
 <label>Table 3.</label>
 <caption>
  <p>Risk of HBV Reactivation Related to Immunosuppressive Therapy for IBD</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" valign="middle" rowspan="1" colspan="1">Risk of reactivation</th>
    <th align="center" valign="middle" rowspan="1" colspan="1">Immunosuppressive agents</th>
    <th align="center" valign="middle" rowspan="1" colspan="1">Antiviral prophylaxis</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">HBsAg-positive</td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="2" colspan="1"> High risk (≥10%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Long-term moderate-to-high dose corticosteroids (prednisone ≥10 mg/day, ≥4 weeks)</td>
    <td valign="top" align="center" rowspan="2" colspan="1">Yes</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">More potent anti-TNF-α (infliximab, adalimumab, certolizumab, and golimumab)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="4" colspan="1"> Moderate risk (1%–10%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Long-term low-dose corticosteroids (prednisone &lt;10 mg/day, ≥4 weeks)</td>
    <td valign="top" align="center" rowspan="4" colspan="1">Yes</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Less potent anti-TNF-α (etanercept)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Cytokine-based therapies (ustekinumab, natalizumab, and vedolizumab)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Immunophilin inhibitors (tacrolimus, cyclosporine)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="2" colspan="1"> Low risk (&lt;1%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Short-term corticosteroids (≤1 week)</td>
    <td valign="top" align="center" rowspan="2" colspan="1">No
     <sup>
      <xref rid="tfn1-ir-2019-09155" ref-type="table-fn">a</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Azathioprine/6-mercaptopurine, methotrexate</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">HBsAg-negative/anti-HBc-positive</td>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="center" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"> High risk (≥ 10%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Not available</td>
    <td valign="top" align="center" rowspan="1" colspan="1">Yes</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="4" colspan="1"> Moderate risk (1%–10%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Long-term moderate-to-high dose corticosteroids (prednisone ≥ 10 mg/day, ≥ 4 weeks)</td>
    <td valign="top" align="center" rowspan="4" colspan="1">No
     <sup>
      <xref rid="tfn1-ir-2019-09155" ref-type="table-fn">a</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Less potent anti-TNF-α (etanercept)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Cytokine-based therapies (ustekinumab, natalizumab, and vedolizumab)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Immunophilin inhibitors (tacrolimus, cyclosporine)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="3" colspan="1"> Low risk (&lt; 1%)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Short-term corticosteroids (≤ 1 week)</td>
    <td valign="top" align="center" rowspan="3" colspan="1">No
     <sup>
      <xref rid="tfn1-ir-2019-09155" ref-type="table-fn">a</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Long-term low-dose corticosteroids (prednisone &lt; 10 mg/day, ≥ 4 weeks)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Azathioprine/6-mercaptopurine, methotrexate</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tfn1-ir-2019-09155">
   <label>a</label>
   <p>Preemptive therapy.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
